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1462Safety of Posaconazole and Sirolimus Coadministration
in Allogeneic Hematopoietic Stem Cell Transplants
David W. Kubiak,1,4 Sophia Koo,1,2,3 Sarah P. Hammond,1,2,3 Philippe Armand,2,3,5
Lindsey R. Baden,1,2,3 Joseph H. Antin,2,3,5 Francisco M. Marty1,2,3Sirolimus is used in allogeneic hematopoietic stem cell transplants (HSCTs) for prevention and treatment of
graft-versus-host disease (GVHD). Posaconazole is used in this population for invasive fungal disease (IFD)
prophylaxis and treatment. As posaconazole strongly inhibits CYP3A4, concurrent administration of siroli-
mus, a CYP3A4 substrate, and posaconazole has been reported to increase sirolimus drug exposure substan-
tially. Coadministration of posaconazole and sirolimus is contraindicated by the manufacturer of
posaconazole. We identified 15 patients who underwent HSCTs at our institution receiving a steady-state
dose of sirolimus who subsequently started posaconazole therapy from January 2006 to March 2009. We
recorded baseline characteristics, drug administration details, and potential adverse effects related to either
drug. All patients underwent HSCTs for treatment of hematologic malignancy. All patients were initially pre-
scribed sirolimus for GVHD prophylaxis and continued therapy after developing GVHD. Twelve patients
(80%) received posaconazole for IFD prophylaxis in the setting of GVHD and 3 (20%) for IFD treatment.
Patients received sirolimus and posaconazole concurrently for a median of 78 days (interquartile range
[IQR] 25-177; range, 6-503). The median daily dose of sirolimus (2 mg/day) before initiation of posaconazole
was reduced 50% to a median daily dose of 1 mg/day at steady state. Six patients experienced sirolimus
trough levels greater than 12 ng/mL during coadministration, but only 1 patient experienced an adverse event
potentially associated with sirolimus exposure during the first month of coadministration. This patient’s
sirolimus dose was empirically reduced by only 30% on posaconazole initiation. Concurrent sirolimus and
posaconazole use seems to be well tolerated with a 33% to 50% empiric sirolimus dose reduction and close
monitoring of serum sirolimus trough levels at the time of posaconazole initiation.
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(HSCTs) [1,2]. Sirolimus binds uniquely to FK
binding protein 12, resulting in the formation of an
immunosuppressive complex that inhibits the
mammalian target of rapamycin, with down-
regulation of T cell proliferation and activation.
Sirolimus has synergistic immunosuppressive effects
when combined with tacrolimus, without overlapping
toxicities or drug interactions [3,4]. Several studies
have observed reduced transplantation-associatedmor-
bidity and mortality with sirolimus-containing GVHD
prophylaxis regimens, with lower rates of grade II to IV
GVHD and superior rates of neutrophil and platelet
engraftment, compared to methotrexate-containing
regimens [5-8].
Sirolimus is extensively metabolized by hepatic
and intestinal cytochrome P450-3A4 (CYP3A4) en-
zymes and is a substrate and inhibitor of P-glycopro-
tein, and plasma concentrations are known to
increase substantially with posaconazole, which
strongly inhibits CYP3A4 [9,10]. Posaconazole has
demonstrated efficacy in preventing invasive fungal
Table 1. Baseline Demographics and Transplantation Char-
acteristics
Cohort Characteristics No. of Patients (%)
Cohort (N) 15
Median age, years (range) 50 (23-63)
Male 9 (60)
Primary underlying disease
AML 5 (33)
Myelodysplastic syndrome 2 (13)
CLL 2 (13)
CML 2 (13)
ALL 2 (13
Aplastic anemia 1 (6)
T cell lymphoblastic lymphoma 1 (6)
HSCT type
Matched related 2 (13)
Matched unrelated 8 (53)
Mismatched related 1 (6)
Mismatched unrelated 4 (26)
AML indicates acute myelogenous leukemia; CLL, chronic lymphocytic
leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblas-
tic leukemia; HSCT, hematopoietic stem cell transplant.
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patients who undergo HSCT with acute GVHD
[11]. Themanufacturer of posaconazole currently con-
traindicates the coadministration of sirolimus with
posaconazole (Noxafil; Schering Corporation, Kenil-
worth, NJ). Voriconazole a triazole antifungal agent
and potent CYP3A4, CYP2C9, and CYP2C19 inhibi-
tor, has been used to prevent IFD in patients who un-
dergo HSCT with GVHD [12]. The manufacturer of
voriconazole also contraindicates coadministration
with sirolimus (Vfend IV; Roerig, New York, NY);
however, feasibility of coadministration with sirolimus
has been reported. Marty et al. [13] found that with an
empiric initial 90% sirolimus dose reduction along
with careful systematic monitoring of sirolimus trough
levels, coadministration was safe and feasible.
There are no clinical data to guide the appropriate
initial empiric dose reduction of sirolimus when coad-
ministration with posaconazole may be clinically indi-
cated. We present a consecutive series of patients at
our institution who required concomitant sirolimus
and posaconazole administration and report the feasi-
bility and safety of such an approach.PATIENTS AND METHODS
Patients who received posaconazole oral suspen-
sion and sirolimus concurrently were identified by
searching medical records of all allogeneic HSCT re-
cipients at our institution from January 2006 to March
2009. Demographics and transplantation details were
recorded. Details of sirolimus and posaconazole use
were recorded, including indications for use; empiric
sirolimus dose adjustments with initiation of posaco-
nazole, posaconazole daily dose, steady-state dose of
sirolimus 1 month after the onset of coadministration,
sirolimus trough levels, and any concomitant medica-
tions that might interact with sirolimus. We also
collected data on concomitant tacrolimus use, tacroli-
mus trough levels, and empiric dose adjustments with
initiation of posaconazole. Any potential adverse ef-
fects related to sirolimus, tacrolimus, or posaconazole
were recorded. The Partners Healthcare Human Re-
search Committee approved this study.RESULTS
Fifteen patients were receiving a steady-state dose
of sirolimus, and 14 of these patients were also receiv-
ing a steady-state dose of tacrolimus when they initi-
ated posaconazole treatment. Demographic data and
transplantation details are summarized inTable 1.Me-
dian age at time of coadministration was 50 years, most
patients were men, the most common malignancy re-
quiring HSCT was acute myelogenous leukemia, and
a high proportion were at high risk for GVHD, withunrelated or mismatched donors. Sirolimus, tacroli-
mus, and posaconazole treatment characteristics are
summarized in Table 2. Patients received sirolimus
and posaconazole concurrently for a median of 78
days (interquartile range [IQR] 25-177; range, 6-
503). All patients were initially prescribed sirolimus
for GVHD prophylaxis, and those who developed
GVHD continued to receive sirolimus as a part of their
GVHD treatment regimen. Most patients (80%) re-
ceived posaconazole for IFD prophylaxis in the setting
of GVHD; the remainder received posaconazole for
IFD treatment. Nine patients had gastrointestinal in-
volvement by acute GVHD, but were able to take
oral medications. No patients received fluconazole
prophylaxis or any other concomitant medications
with the potential to induce or inhibit CYP3A4 iso-
zymes or cause a relevant pharmacokinetic (PK) drug
interaction with either sirolimus or tacrolimus during
the study period.
Themedian daily dose of sirolimus before initiation
of posaconazole was 2 mg (range, 1-3 mg). At initiation
of posaconazole and sirolimus coadministration, the
daily sirolimusdosewasempirically reducedbyamedian
of 50% (IQR, 0%-50%; range, 0%-90%) in the cohort.
After 7 days of coadministration, the median daily siro-
limus dose was 33% (IQR, 0%-50%; range, 250% to
83%) less than the baseline sirolimus dose before coad-
ministration. A single patient required a 50% sirolimus
dose increase from baseline. There were no differences
in the percent reduction in sirolimus dose among the
9 patients with gastrointestinal involvement with
GVHD when compared to the rest of the cohort.
At initiation of posaconazole and tacrolimus coad-
ministration, the median daily tacrolimus dose was
empirically reduced by 33% (IQR, 0%-50%; range,
0%-67%). The median steady-state dose was 30%
(IQR, 0%-50%; range, 2100% to 70%) less than the
Table 2. Drug Treatment Characteristics and Coadministration Parameters
Characteristic
Initial indication for sirolimus (N, %)
GVHD prophylaxis 15 (100)
Indication for posaconazole (N, %)
IFD prophylaxis in setting of GVHD 12 (80)
Treatment of proven-probable IFD 3 (20)
Total daily dose of posaconazole (N, %)
600 mg 13 (87)
800 mg 2 (13)
Duration of sirolimus and posaconazole coadministration, days (IQR; range) 78 (25-177; 6-503)
Concomitant tacrolimus administration (N, %) 14 (93)
Drug parameter At start of coadministration (IQR; range) At steady state of coadministration (IQR; range)
Median daily sirolimus dose, mg 2 (1-3; 1-3) 1 (0.5-1.5; 0.3-3)
Median serum sirolimus trough level, ng/mL 5.5 (3.8-8.5; 2.8-28.3) 5.3 (4.1-6.4; 2.8-12.1)
Median daily sirolimus dose reduction, % 50 (0-50; 0-90) 33 (0-50; 250 to 83)*
Median daily sirolimus dose reduction, excluding 1
patient with a possible drug-related adverse event, %
50 (0-50; 0-90) 42 (0-50; 250 to 83)*
GVHD indicates graft-versus-host disease; IFD, invasive fungal disease; IQR, interquartile range.
*Negative numbers indicate an increase in sirolimus or tacrolimus dosing.
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median daily tacrolimus dose (mg) was 2.3 (IQR, 1.5-
3; range, 1-8) before coadministration and 1.5 (IQR,
1-2; range, 0.5-6) after coadministration. The median
serum tacrolimus trough level (ng/mL) was 5.3 (IQR,
4-6.1; range, 2.8-8.7) before coadministration and 5.2
(IQR, 3.5-8.1; range, 1.7-10) after coadministration.
Posaconazole levels were not assessed.
Safety
The majority of patients with initial empiric siroli-
mus or tacrolimus dosage reductions tolerated the co-
administration of posaconazole well and did not
experience any drug-related adverse events or eleva-
tions in serum creatinine from baseline values. There
were 6 patients who had sirolimus trough levels .12
ng/mL during the first month of coadministration
[4]. Only a single patient with an elevated sirolimus
level experienced an adverse event during the first
month of coadministration potentially related to in-
creased sirolimus levels. This patient was prescribed
posaconazole for IFD prophylaxis in the setting of
GVHD and developed increased lactate dehydroge-
nase levels (peak, 947 U/L), thrombocytopenia (plate-
let nadir, 37 k/mL), and occasional schistocytes on
blood smear 2 weeks after starting coadministration.
Sirolimus was discontinued due to concern for throm-
botic microangiopathy. His sirolimus dose was
initially reduced by 30% at the start of coadministra-
tion and his sirolimus trough level increased from 4.1
ng/mL to a peak of 19.5 ng/mL 9 days later, a week
before his suspected TMA developed. Sirolimus was
subsequently discontinued and the patient’s thrombo-
cytopenia and elevated lactate dehydrogenase normal-
ized 10 weeks later without further sequelae.
We could not confirm if this event was attributable
to the coadministration of posaconazole and sirolimusor tacrolimus. No patients in our cohort developed
veno-occlusive disease or sirolimus-associated neph-
rotoxicity during coadministration.DISCUSSION
Concurrent sirolimus and posaconazole use
seemed to be well tolerated with an empiric sirolimus
dose reduction of approximately 33% to 50% and
close monitoring of serum sirolimus trough concen-
trations the week after posaconazole initiation. Only
1 patient experienced an adverse event potentially re-
lated to elevated sirolimus levels during the first month
of posaconazole coadministration with sirolimus. The
serum concentrations of sirolimus and tacrolimus were
not significantly elevated in this patient; however,
upon discontinuation of sirolimus, the patient’s symp-
toms resolved without sequelae. Five other patients
had at least 1 elevated sirolimus trough level .12
ng/mL during the first month of coadministration
without any observed adverse events. Most patients re-
ceived extended courses of both sirolimus and posaco-
nazole without any notable adverse events. Of note,
concurrent tacrolimus and posaconazole use was also
well tolerated with a median 30% tacrolimus dose re-
duction at the start of tacrolimus and posaconazole co-
administration with close monitoring of serum
tacrolimus trough concentrations. Although this expe-
rience is relatively small, it suggests that sirolimus and
posaconazole can be safely coadministered with an ap-
propriate initial sirolimus dose reduction and close se-
rum concentration monitoring.
Data on coadministration of sirolimus and posaco-
nazole are sparse. A PK study of posaconazole coadmi-
nistered with sirolimus in 12 healthy subjects reported
that posaconazole dosed at 400 mg twice daily
increased the sirolimus area under the curve by
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effect of voriconazole coadministration on sirolimus
PKs voriconazole coadministration causes an 11-fold
increase in the area under the curve and a 7-fold in-
crease in the sirolimusCmax, requiring a 90% initial em-
piric sirolimus dose reduction upon coadministration
(Vfend IV; Roerig, New York, NY) [13]. In this study
[14], however, these agents were only coadministered
for a single day and not in the presence of steady-state
sirolimus serum concentrations. To our knowledge,
no studies have examined the effect of fluconazole coad-
ministration on the PKs of sirolimus. Additionally, we
found no publications assessing the clinical feasibility
of sirolimus and fluconazole coadministration. Fluco-
nazole is a weaker CYP2C19, CYP2C9, and CYP3A4
inhibitor compared to posaconazole or voriconazole
[15]. Initial empiric dose adjustments of sirolimus and
tacrolimus upon coadministration with fluconazole
have largely been inferred from studies of other triazole
antifungal agents. Some experts have suggested that an
initial empiric dose adjustment of 50% to 70% of siro-
limus is necessary when initiating fluconazole at doses
greater than or equal to 200 mg daily; however, empir-
ical data are lacking [16].
In conclusion, an empiric sirolimus dose reduction
of at least 33% to 50% is warranted when initiating
posaconazole therapy, followed by close serum trough
concentration monitoring. Furthermore, prolonged
coadministration of sirolimus and posaconazole is fea-
sible and seems to be well tolerated in this population.
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